abstract: UNASSIGNED: The purpose of this study was to a) determine the heart rate variability (HRV) and saliva markers of immunity (salivary immunoglobulin A; sIgA) and stress ( @entity5941 ; @entity5475 ) responses to chronic training in elite swimmers with a disability; and b) identify the relationships between HRV, sIgA, @entity5475 and training volume. Eight members of a high performance Paralympic swimming program were monitored for their weekly resting HRV, sIgA and @entity5475 levels in the 14 weeks leading up to a major international competition. The 14 week training program included aerobic, anaerobic, power and speed, and taper training phases, while also incorporating two swimming step tests and two swimming competitions. Specific time (root mean square of the successive differences; RMSSD) and frequency (high frequency normalized units [HFnu]) domain measures, along with non-linear indices (standard deviation of instantaneous RR variability; @entity15757 and short term fractal scaling exponent; a1) of HRV were used for all analyses with effects examined using magnitude-based inferences. Relationships between HRV and saliva markers were identified by Spearman rank rho (  ) correlation coefficients. Compared with week 1, @entity15757 was very likely lower (96/4/0, ES = -2.21), while @entity5475 was very likely elevated (100/0/0, ES = 2.32) at the beginning of week 7 for all athletes. The training program did not alter HRV or saliva whereas competition did. There were also no apparent differences observed for HRV, sIgA and @entity5475 between each of the training phases during the 14 week swimming program. Correlations were observed between @entity5475 and @entity15757 (   = -0.212, p<0.05), along with @entity5475 and mean HR (   = 0.309, p<0.05). These results show that high level national competition influences depresses HRV ( @entity15757 ) and increases saliva biomarkers of stress ( @entity5475 ). It appears that a well-managed and periodised swimming program can maintain these indices within normal baseline levels. The study also highlighted the parasympathetic nervous system influence on @entity5475 .

title: Effect of Chronic Training on Heart Rate Variability, Salivary IgA and XXXX in Elite Swimmers with a Disability.

entities_list: @entity5941 :: ('276', 'Gene') :: ['salivary alpha-amylase']

answer: @entity5941 :: (276,Gene) :: ['Salivary Alpha-Amylase']


abstract: @entity1 telomerase RNA ( @entity28373 ) expression in skin was examined by in situ hybridization analysis. All newborn foreskins examined (n = 5) expressed @entity28373 in epidermal basal cells at moderate levels. Telomerase RNA was not detectable in most adult specimens from sun protected areas (six of seven), whereas all samples obtained from sun exposed areas (n = 8) showed moderate @entity28373 signals in epidermal basal cells. Telomerase RNA was also detected at moderate to strong levels in basal cells of @entity1569 , @entity5526 , and the proliferative cells of the anagen hair bulb. @entity1491 samples (14 of 15) had moderate to high @entity28373 expression throughout the entire @entity5 , whereas @entity957 (seven of eight) showed variable intensities of @entity28373 expression but only in the cells at the periphery of @entity5 nests. All @entity320 examined (n = 5) had moderate @entity28373 expression in all @entity5 cells. The @entity28373 signal intensities in @entity1489 did not correlate with the age or sex of the donors, the clinical history of the lesions, or the histologic subtypes. To address whether @entity28373 expression correlated with the proliferative state, sequential sections were stained with anti-Ki-67 antibody, a proliferation marker. In newborn foreskins, @entity957 , and @entity1491 , the distributions of @entity28373 and Ki-67 were similar but not always identical. Telomerase RNA was more abundant than Ki-67 in the basal and suprabasal layer of newborn foreskins, suggesting that @entity28373 expression is present both in actively cycling and in resting cells.

title: In situ hybridization analysis of the expression of XXXX telomerase RNA in normal and pathologic conditions of the skin.

entities_list: @entity1569 :: ('MESH:D011565', 'Disease') :: ['psoriasis']

entities_list: @entity1489 :: ('MESH:D012878', 'Disease') :: ['skin tumors']

entities_list: @entity957 :: ('MESH:D002294', 'Disease') :: ['squamous cell carcinomas']

entities_list: @entity5526 :: ('MESH:D003877', 'Disease') :: ['contact dermatitis']

entities_list: @entity320 :: ('MESH:D008545', 'Disease') :: ['melanomas']

entities_list: @entity1491 :: ('MESH:D002280', 'Disease') :: ['basal cell carcinomas', 'Basal cell carcinoma']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: Ninety-three (93) cases of acute @entity1778 were assessed using flow cytometry and cytochemistry and assigned to one of four categories: myeloid, lymphoid, biphenotypic, and non-diagnostic. In @entity1778 designated as @entity981 or @entity3052 by both methodologies, there was lineage agreement in all but 3 of 71 cases (95.8%). However, when nondiagnostic or biphenotypic diagnoses made by either methodology were included, complete agreement occurred in only 77.4% of cases. Of 37 cases designated myeloid origin by flow cytometry, 33 (89.2%) were read as myeloid by cytochemistry. The four discordant diagnosis were read as lymphoid (2) or as non-diagnostic (2). Eighty percent of @entity706 were diagnosed as such by both flow cytometry and cytochemistry; one early B cell @entity981 was diagnosed as myeloid and 8 as non-diagnostic. Fifty percent (50%) of flow cytometry defined T-cell @entity981 were considered non-diagnostic by cytochemistry as compared to 17% of the total @entity981 group. Of the remaining four designated non-T cell @entity981 by flow cytometry and non-diagnostic by cytochemistry, three were read by flow cytometry to be standard pre-B @entity981 and one an early B-cell @entity981 . Only 2/9 @entity1778 considered biphenotypic by flow were identified as such by cytochemistry. Given (1) the potential importance of non-lineage expression in the prognosis of myeloid and @entity706 , (2) cytochemistry's impaired ability to diagnose biphenotypic, T-cell, and @entity2799 , and (3) the increased costs incurred in diagnosis when both modalities are used, perhaps it is time to re-examine the utility of performing both flow cytometry and cytochemistry as initial testing for @entity1778 categorization.

title: Flow cytometry with or without cytochemistry for the diagnosis of XXXX ?

entities_list: @entity2799 :: ('MESH:D015473', 'Disease') :: ['promyelocytic leukemias']

entities_list: @entity706 :: ('MESH:D008223', 'Disease') :: ['lymphoid leukemias']

entities_list: @entity1778 :: ('MESH:D007938', 'Disease') :: ['leukemias', 'leukemia']

answer: @entity3052 :: (MESH:D015470,Disease) :: ['acute leukemias']


abstract: Eleven pediatric @entity981 @entity1 were investigated for chromosomal @entity2007 by interphase cytogenetics using chromosome specific (peri)centromeric probes for all the somatic and sex chromosomes. Results were compared with metaphase cytogenetic and flow cytometric derived DNA @entity2007 data. Experiments performed on normal @entity1 cells using chromosome specific (peri)centromeric probes indicated that disomy could be recognized in a range of 89.1+/-2.7% (12.9)-96.8+/-0.2% (0.9) for the somatic chromosomes and in 98.1+/-0.4% (1.3) for the sex chromosomes. Using the cutoff level of the mean false monosomy and trisomy in the control cells +2 S.D., chromosome loss or gain for the somatic chromosomes could be revealed beyond a clonal ratio of 3.6-13.2% and 1.1-6.8%, respectively. The same value for the sex chromosomes was 3.5% and 0%, respectively. In 5 of 11 @entity1 the leukemic cells proved to be diploid with all three methods at both gross DNA and chromosome levels. Interphase cytogenetics revealed chromosome loss or gain in all of the remaining six @entity1 , however, the metaphase analysis indicated numerical aberration in only two @entity1 . In one of them only the increased chromosome number could have been detected without identifying the chromosomes involved and in the other one the two methods indicated trisomy for a different chromosome. Flow cytometric data showed @entity2007 in three of the six @entity1778 @entity1 . The results suggest that interphase cytogenetics might be more accurate compared with flow cytometry and metaphase analysis to reveal @entity2007 .

title: Combined metaphase, interphase cytogenetic, and flow cytometric analysis of DNA content of pediatric XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity1778 :: ('MESH:D007938', 'Disease') :: ['aneuploid leukemia']

entities_list: @entity2007 :: ('MESH:D000782', 'Disease') :: ['aneuploidy']

entities_list: @entity981 :: ('MESH:D054198', 'Disease') :: ['acute lymphoid leukemia']

answer: @entity981 :: (MESH:D054198,Disease) :: ['acute lymphoblastic leukemia']


abstract: BACKGROUND: @entity227 following @entity64 are frequently subtle and are often overlooked. Even though these @entity227 may be less overt in nature, they are still debilitating to survivors. @entity227 have been shown to negatively impact cognition, mobility, and activities of daily living (ADL). There is little consistency across healthcare facilities regarding protocol for assessing vision following @entity64 . OBJECTIVE: This research was designed to describe a profile for @entity1 exhibiting @entity227 following @entity64 , examine the role of occupational therapists in vision assessment, and discuss a potential model to provide a protocol for collaboration with an eye care professional as part of the rehabilitation team. METHODS: The sample consisted of 131 @entity1 in an inpatient rehabilitation (IPR) unit who were identified as having potential @entity227 . Occupational therapists on an IPR unit administered initial vision screenings and these @entity1 were subsequently evaluated by the consulting optometrist. Frequencies were calculated for the appearance of functional symptoms, diagnoses, and recommendations. Correlations were also computed relating diagnoses and recommendations made. RESULTS: All @entity1 referred by the occupational therapist for optometrist evaluation had at least one visual diagnosis. The most frequent visual diagnoses included: saccades (77.7%), pursuits (61.8%), and convergence (63.4%). There was also a positive correlation between number of functional symptoms seen by occupational therapists and visual diagnoses made by the optometrist (r    =    0.209, P    =    0.016). CONCLUSION: Results of this study support the need for vision assessment following @entity64 in IPR, confirm the role of occupational therapists in vision assessment, and support the need for an optometrist as a member of the rehabilitation team.

title: Review of experience with a collaborative eye care clinic in inpatient XXXX rehabilitation.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity227 :: ('MESH:D014786', 'Disease') :: ['Visual deficits', 'visual deficits']

answer: @entity64 :: (MESH:D020521,Disease) :: ['stroke']


abstract: The purpose of this study was to examine avidity of immunoglobulin G (IgG) antibody for surface antigens of @entity2523 in sera from @entity1 with @entity7278 . The antigens used were whole cell antigens, lipopolysaccharides (LPS), and fimbriae of non-invasive @entity36978 and invasive 16-1. Serum IgG titers for the P. gingivalis antigens were measured by enzyme-linked immunosorbent assay (ELISA) before and after periodontal initial preparation. IgG avidity was measured by @entity21677 dissociation ELISA. IgG titers for the whole cell antigens of 16-1, LPS, and the fimbria antigens from both @entity2523 strains were significantly higher in the @entity1 group than those in the control group, whereas values for avidities were significantly lower in @entity1 sera. Although we found a statistically significant decrease in the IgG titers of @entity1 following initial preparation, avidities against the fimbria antigen of invasive 16-1 strain increased. The present study showed that IgG antibodies elicited in @entity1 were different in their ability to respond to invasive @entity2523 16-1 and to non-invasive 33277. The @entity1 sera with high IgG titers demonstrated low values for avidity, suggesting that IgG responses in @entity1 play a limited role in colonization inhibition or elimination of @entity2523 . The data indicate that periodontally healthy individuals may have highly functional antibodies which may protect against @entity2523 colonization. Our findings suggest that the ability to produce functional antibodies in the @entity1 group is lower than that in the periodontally healthy group, but the functional antibodies can be induced by the initial preparation.

title: Dynamics of serum immunoglobulin G avidity for XXXX in @entity7278 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity7278 :: ('MESH:D055113', 'Disease') :: ['adult periodontitis']

entities_list: @entity21677 :: ('MESH:C034281', 'Chemical') :: ['diethylamine']

entities_list: @entity2523 :: ('837', 'Species') :: ['Porphyromonas gingivalis', 'P. gingivalis']

answer: @entity2523 :: (837,Species) :: ['Porphyromonas gingivalis']


abstract: The purpose of this study was to examine avidity of immunoglobulin G (IgG) antibody for surface antigens of @entity2523 in sera from @entity1 with @entity7278 . The antigens used were whole cell antigens, lipopolysaccharides (LPS), and fimbriae of non-invasive @entity36978 and invasive 16-1. Serum IgG titers for the P. gingivalis antigens were measured by enzyme-linked immunosorbent assay (ELISA) before and after periodontal initial preparation. IgG avidity was measured by @entity21677 dissociation ELISA. IgG titers for the whole cell antigens of 16-1, LPS, and the fimbria antigens from both @entity2523 strains were significantly higher in the @entity1 group than those in the control group, whereas values for avidities were significantly lower in @entity1 sera. Although we found a statistically significant decrease in the IgG titers of @entity1 following initial preparation, avidities against the fimbria antigen of invasive 16-1 strain increased. The present study showed that IgG antibodies elicited in @entity1 were different in their ability to respond to invasive @entity2523 16-1 and to non-invasive 33277. The @entity1 sera with high IgG titers demonstrated low values for avidity, suggesting that IgG responses in @entity1 play a limited role in colonization inhibition or elimination of @entity2523 . The data indicate that periodontally healthy individuals may have highly functional antibodies which may protect against @entity2523 colonization. Our findings suggest that the ability to produce functional antibodies in the @entity1 group is lower than that in the periodontally healthy group, but the functional antibodies can be induced by the initial preparation.

title: Dynamics of serum immunoglobulin G avidity for @entity2523 in XXXX .

answer: @entity7278 :: (MESH:D055113,Disease) :: ['adult periodontitis']


abstract: To understand the influence of the ascending path linking area 17 to area 18 of visual cortices, experiments were carried out in which a small neuronal population of area 17 was inactivated with @entity1246 , while unitary responses were recorded in area 18. In the latter, cells are identified as belonging to the simple or complex family according to their firing pattern evoked in response to sine-wave gratings scrolling through the receptive fields. Anesthetized @entity468 were prepared for single-cell recordings. In area 17, a @entity1246 -containing pipette was placed in superficial layers in order to inactivate reversibly a small neuronal population. Prior to blockade, the orientation tuning curves were obtained in both areas and the difference in optimal orientation between areas 17 and 18 was recorded. In area 18, cells were classified as simple or complex. The strategy was to study the reaction of neurons in area 18 prior to, during and after area 17 @entity308 . In most simple cells, whenever the difference in orientation was in the iso-range, that is when the difference in optimal orientations of the injected site (in area 17) and of the neuron in area 18 was less than 30 degrees, the @entity1246 application produced a decline of the evoked discharges, whereas @entity1246 injection augmented the evoked firing rate when the difference was in the cross-range (>60 degrees). In contrast to simple cells, @entity1246 @entity308 enhanced the responses in the majority of complex cells with like orientations in both areas. When the difference between recording sites was in the cross-range, then area 17 @entity308 produced @entity8327 . A tangential penetration of the injecting pipette, allowing injection of different orientation sites while testing the same unit in area 18, revealed that the latter could react with an enhancement or a decline of the responses as the injecting pipette shifted from iso (or cross) to cross (or iso) disparity in optimal orientations between areas 17 and 18. These results suggest that the path connecting area 17 to area 18 may be functionally discriminated on the basis of the orientation domain and cell types. In addition, our data suggest that the ascending visual streams are required to generate orientation specificity in area 18.

title: Influences of area 17 on neuronal activity of simple and complex cells of area 18 in XXXX .

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

entities_list: @entity8327 :: ('MESH:D004881', 'Disease') :: ['weaker evoked firing']

answer: @entity468 :: (9685,Species) :: ['cats']


abstract: @entity2689 ( @entity2689 ) is a @entity2008 with a frequency of 1/2,000-3,000 among female live births. Characteristic findings are short stature and @entity444 . Short and @entity135 , low posterior hairline, broad chest, widespread nipples, @entity14209 , short 4th and 5th metacarpals, multiple @entity8205 , primary @entity2588 , lack of secondary sexual characteristics, cardiovascular and @entity8 are the most common presentations. Most of the cases are infertile. Spontaneous pregnancy is unusual and the risk for @entity154 , @entity2208 , @entity2209 and @entity2007 is increased. Fifty percent of the @entity1 have classical @entity2689 (45,X). However mosaicism of 45,X/47,XXX is rare and accounts for 1.7% of the @entity2689 cases. Some cases may not reflect the characteristic phenotype. Some cases with normal height, normal menstrual cyclus and fertility have been defined before. The case we present herein is a 26 years old @entity1 who was admitted to our clinic due to recurrent @entity393 . In her medical history she had @entity6 and @entity5 , in her family history her mother had recurrent @entity393 . The @entity1 's first, third, fourth, fifth and sixth pregnancies had resulted in @entity2208 in the first trimester. She had a healthy daughter with 46,XX karyotype from her second pregnancy. A 45,X[8]/47,XXX[12] karyotype was detected by conventional cytogenetic analysis of the @entity1 who did not have dysmorphic findings. The mosaicism was confirmed by FISH analysis with @entity12563 probe. Of the 100 cells evaluated, 65 of them had 3 signals of X chromosome while 35 had 1 signal. We present the case because of its scarcity in the literature.

title: A fertile XXXX with 45X/47XXX mosaicism.

entities_list: @entity1 :: ('9606', 'Species') :: ['patient', 'woman', 'patients']

entities_list: @entity135 :: ('MESH:D006258', 'Disease') :: ['webbed neck']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['renal anomalies']

entities_list: @entity154 :: ('MESH:D000013', 'Disease') :: ['congenital anomaly']

entities_list: @entity2208 :: ('MESH:D000022', 'Disease') :: ['spontaneous abortions', 'spontaneous abortion']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['type 1 diabetes mellitus']

entities_list: @entity2209 :: ('MESH:D050497', 'Disease') :: ['stillbirth']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['endometrium cancer']

entities_list: @entity8205 :: ('MESH:D009508', 'Disease') :: ['pigmented nevi']

entities_list: @entity2689 :: ('MESH:D014424', 'Disease') :: ['monosomy X', 'TS', 'Turner syndrome']

entities_list: @entity14209 :: ('MESH:C564510', 'Disease') :: ['cubitus valgus']

entities_list: @entity444 :: ('MESH:D006059', 'Disease') :: ['gonadal dysgenesis']

entities_list: @entity2008 :: ('MESH:D002869', 'Disease') :: ['sex chromosome abnormality']

entities_list: @entity393 :: ('MESH:D034381', 'Disease') :: ['pregnancy loss']

entities_list: @entity2588 :: ('MESH:D000568', 'Disease') :: ['amenorrhea']

answer: @entity1 :: (9606,Species) :: ['patient']


abstract: @entity1358 ( @entity1358 ) has a poor prognosis. Conventional treatment strategies, including chemotherapy and hormonal therapy, have limited value. Although encouraging results have been achieved in terms of objective response using immunological manipulations, no conclusive studies yet exist with a controlled comparative evaluation of survival. Therefore, the present study was undertaken, which compared one of the present (and presumed best) treatments, @entity13236 ( @entity1199 / @entity3027 ) and @entity440 , with a control arm of @entity440 only. @entity440 has been shown to potentiate in vivo anti- @entity5 activity of @entity1199 , and because of its non-toxic behaviour it was included in both groups. The study was open, randomized and included seven institutions in Sweden. The @entity1 were stratified according to the different centres involved. An interim analysis was planned when a minimum of 100 @entity1 were evaluable. The 128 @entity1 finally included had a histologically documented metastatic @entity1358 , with a life expectancy of more than 3 months, a performance status WHO 0-2 and no prior chemo- or immunotherapy. Informed consent was obtained from each @entity1 . The @entity1 randomized to the control arm (n = 63) received only @entity440 40 mg p.o. daily for at least 1 year or until progression. The @entity1 (n = 65) randomized to biotherapy received subcutaneous recombinant @entity1199 , leucocyte @entity3027 in a treatment cycle of 42 days, as well as @entity440 p.o. In the absence of undue @entity137 or disease progression, these @entity1 received one additional treatment cycle of 42 days followed by maintenance treatment, consisting of 5 days therapy every 4 weeks, for 1 year, or until proven progression. Only two @entity1 in the @entity440 -only group received immunotherapy when the disease progressed, but without any beneficial effect. All @entity1 received appropriate local treatment when indicated. The interim analysis demonstrated no survival advantage for either group, and therefore further inclusion of @entity1 was stopped. The median follow-up was 11 months (range 0.4-48 months). The final survival analysis showed no significant differences between the two treatment arms in so far as comparison from the day of diagnosis of @entity66 , from the day of first evidence of metastatic spread, or from the onset of treatment. This was valid both when the evaluation was performed with regard to intention to treat and when the analysis was directed only to @entity1 that managed at least one treatment cycle (42 days) of @entity1199 / @entity3027 . The adverse effects were more pronounced in the @entity1199 / @entity3027 group. Although the number of @entity1 is limited, the results raise doubt concerning immunotherapy with @entity1199 and @entity3027 as a routine treatment in the management of advanced @entity1358 . The difference in cost of drugs and health care (drug costs per @entity1 : @entity1199 / @entity3027  27000 vs @entity440  360) as well as adverse effects caused by @entity1199 / @entity3027 are also factors of importance. The study emphasizes the need for more effort to find the 'optimal schedule' of immunotherapy, as well as the need for randomized controlled studies before approval of a new treatment in the routine setting.

title: XXXX -a randomized evaluation of @entity440 vs @entity1199 , alpha-interferon (leucocyte) and @entity440 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity440 :: ('MESH:D013629', 'Chemical') :: ['tamoxifen', 'Tamoxifen']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['primary disease']

entities_list: @entity13236 :: ('50616', 'Gene') :: ['interleukin 2/interferon-alpha']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour']

entities_list: @entity1358 :: ('MESH:D002292', 'Disease') :: ['Metastatic renal cell carcinoma', 'RCC']

answer: @entity1358 :: (MESH:D002292,Disease) :: ['Survival in renal cell carcinoma']


abstract: @entity1358 ( @entity1358 ) has a poor prognosis. Conventional treatment strategies, including chemotherapy and hormonal therapy, have limited value. Although encouraging results have been achieved in terms of objective response using immunological manipulations, no conclusive studies yet exist with a controlled comparative evaluation of survival. Therefore, the present study was undertaken, which compared one of the present (and presumed best) treatments, @entity13236 ( @entity1199 / @entity3027 ) and @entity440 , with a control arm of @entity440 only. @entity440 has been shown to potentiate in vivo anti- @entity5 activity of @entity1199 , and because of its non-toxic behaviour it was included in both groups. The study was open, randomized and included seven institutions in Sweden. The @entity1 were stratified according to the different centres involved. An interim analysis was planned when a minimum of 100 @entity1 were evaluable. The 128 @entity1 finally included had a histologically documented metastatic @entity1358 , with a life expectancy of more than 3 months, a performance status WHO 0-2 and no prior chemo- or immunotherapy. Informed consent was obtained from each @entity1 . The @entity1 randomized to the control arm (n = 63) received only @entity440 40 mg p.o. daily for at least 1 year or until progression. The @entity1 (n = 65) randomized to biotherapy received subcutaneous recombinant @entity1199 , leucocyte @entity3027 in a treatment cycle of 42 days, as well as @entity440 p.o. In the absence of undue @entity137 or disease progression, these @entity1 received one additional treatment cycle of 42 days followed by maintenance treatment, consisting of 5 days therapy every 4 weeks, for 1 year, or until proven progression. Only two @entity1 in the @entity440 -only group received immunotherapy when the disease progressed, but without any beneficial effect. All @entity1 received appropriate local treatment when indicated. The interim analysis demonstrated no survival advantage for either group, and therefore further inclusion of @entity1 was stopped. The median follow-up was 11 months (range 0.4-48 months). The final survival analysis showed no significant differences between the two treatment arms in so far as comparison from the day of diagnosis of @entity66 , from the day of first evidence of metastatic spread, or from the onset of treatment. This was valid both when the evaluation was performed with regard to intention to treat and when the analysis was directed only to @entity1 that managed at least one treatment cycle (42 days) of @entity1199 / @entity3027 . The adverse effects were more pronounced in the @entity1199 / @entity3027 group. Although the number of @entity1 is limited, the results raise doubt concerning immunotherapy with @entity1199 and @entity3027 as a routine treatment in the management of advanced @entity1358 . The difference in cost of drugs and health care (drug costs per @entity1 : @entity1199 / @entity3027  27000 vs @entity440  360) as well as adverse effects caused by @entity1199 / @entity3027 are also factors of importance. The study emphasizes the need for more effort to find the 'optimal schedule' of immunotherapy, as well as the need for randomized controlled studies before approval of a new treatment in the routine setting.

title: @entity1358 -a randomized evaluation of @entity440 vs XXXX , alpha-interferon (leucocyte) and @entity440 .

answer: @entity1199 :: (3558,Gene) :: ['interleukin 2']


abstract: @entity1358 ( @entity1358 ) has a poor prognosis. Conventional treatment strategies, including chemotherapy and hormonal therapy, have limited value. Although encouraging results have been achieved in terms of objective response using immunological manipulations, no conclusive studies yet exist with a controlled comparative evaluation of survival. Therefore, the present study was undertaken, which compared one of the present (and presumed best) treatments, @entity13236 ( @entity1199 / @entity3027 ) and @entity440 , with a control arm of @entity440 only. @entity440 has been shown to potentiate in vivo anti- @entity5 activity of @entity1199 , and because of its non-toxic behaviour it was included in both groups. The study was open, randomized and included seven institutions in Sweden. The @entity1 were stratified according to the different centres involved. An interim analysis was planned when a minimum of 100 @entity1 were evaluable. The 128 @entity1 finally included had a histologically documented metastatic @entity1358 , with a life expectancy of more than 3 months, a performance status WHO 0-2 and no prior chemo- or immunotherapy. Informed consent was obtained from each @entity1 . The @entity1 randomized to the control arm (n = 63) received only @entity440 40 mg p.o. daily for at least 1 year or until progression. The @entity1 (n = 65) randomized to biotherapy received subcutaneous recombinant @entity1199 , leucocyte @entity3027 in a treatment cycle of 42 days, as well as @entity440 p.o. In the absence of undue @entity137 or disease progression, these @entity1 received one additional treatment cycle of 42 days followed by maintenance treatment, consisting of 5 days therapy every 4 weeks, for 1 year, or until proven progression. Only two @entity1 in the @entity440 -only group received immunotherapy when the disease progressed, but without any beneficial effect. All @entity1 received appropriate local treatment when indicated. The interim analysis demonstrated no survival advantage for either group, and therefore further inclusion of @entity1 was stopped. The median follow-up was 11 months (range 0.4-48 months). The final survival analysis showed no significant differences between the two treatment arms in so far as comparison from the day of diagnosis of @entity66 , from the day of first evidence of metastatic spread, or from the onset of treatment. This was valid both when the evaluation was performed with regard to intention to treat and when the analysis was directed only to @entity1 that managed at least one treatment cycle (42 days) of @entity1199 / @entity3027 . The adverse effects were more pronounced in the @entity1199 / @entity3027 group. Although the number of @entity1 is limited, the results raise doubt concerning immunotherapy with @entity1199 and @entity3027 as a routine treatment in the management of advanced @entity1358 . The difference in cost of drugs and health care (drug costs per @entity1 : @entity1199 / @entity3027  27000 vs @entity440  360) as well as adverse effects caused by @entity1199 / @entity3027 are also factors of importance. The study emphasizes the need for more effort to find the 'optimal schedule' of immunotherapy, as well as the need for randomized controlled studies before approval of a new treatment in the routine setting.

title: @entity1358 -a randomized evaluation of XXXX vs @entity1199 , alpha-interferon (leucocyte) and @entity440 .

answer: @entity440 :: (MESH:D013629,Chemical) :: ['tamoxifen']


abstract: @entity1358 ( @entity1358 ) has a poor prognosis. Conventional treatment strategies, including chemotherapy and hormonal therapy, have limited value. Although encouraging results have been achieved in terms of objective response using immunological manipulations, no conclusive studies yet exist with a controlled comparative evaluation of survival. Therefore, the present study was undertaken, which compared one of the present (and presumed best) treatments, @entity13236 ( @entity1199 / @entity3027 ) and @entity440 , with a control arm of @entity440 only. @entity440 has been shown to potentiate in vivo anti- @entity5 activity of @entity1199 , and because of its non-toxic behaviour it was included in both groups. The study was open, randomized and included seven institutions in Sweden. The @entity1 were stratified according to the different centres involved. An interim analysis was planned when a minimum of 100 @entity1 were evaluable. The 128 @entity1 finally included had a histologically documented metastatic @entity1358 , with a life expectancy of more than 3 months, a performance status WHO 0-2 and no prior chemo- or immunotherapy. Informed consent was obtained from each @entity1 . The @entity1 randomized to the control arm (n = 63) received only @entity440 40 mg p.o. daily for at least 1 year or until progression. The @entity1 (n = 65) randomized to biotherapy received subcutaneous recombinant @entity1199 , leucocyte @entity3027 in a treatment cycle of 42 days, as well as @entity440 p.o. In the absence of undue @entity137 or disease progression, these @entity1 received one additional treatment cycle of 42 days followed by maintenance treatment, consisting of 5 days therapy every 4 weeks, for 1 year, or until proven progression. Only two @entity1 in the @entity440 -only group received immunotherapy when the disease progressed, but without any beneficial effect. All @entity1 received appropriate local treatment when indicated. The interim analysis demonstrated no survival advantage for either group, and therefore further inclusion of @entity1 was stopped. The median follow-up was 11 months (range 0.4-48 months). The final survival analysis showed no significant differences between the two treatment arms in so far as comparison from the day of diagnosis of @entity66 , from the day of first evidence of metastatic spread, or from the onset of treatment. This was valid both when the evaluation was performed with regard to intention to treat and when the analysis was directed only to @entity1 that managed at least one treatment cycle (42 days) of @entity1199 / @entity3027 . The adverse effects were more pronounced in the @entity1199 / @entity3027 group. Although the number of @entity1 is limited, the results raise doubt concerning immunotherapy with @entity1199 and @entity3027 as a routine treatment in the management of advanced @entity1358 . The difference in cost of drugs and health care (drug costs per @entity1 : @entity1199 / @entity3027  27000 vs @entity440  360) as well as adverse effects caused by @entity1199 / @entity3027 are also factors of importance. The study emphasizes the need for more effort to find the 'optimal schedule' of immunotherapy, as well as the need for randomized controlled studies before approval of a new treatment in the routine setting.

title: @entity1358 -a randomized evaluation of @entity440 vs @entity1199 , alpha-interferon (leucocyte) and XXXX .

answer: @entity440 :: (MESH:D013629,Chemical) :: ['tamoxifen']


abstract: OBJECTIVE: To explore the intervention of @entity7651 on signal transduction and activating transcription factor expression of @entity31 ( @entity31 ) @entity1 . METHODS: Recruited were @entity31 @entity1 at Outpatient Department of @entity21149 , Inpatient Department of @entity21149 , Center for Digestive Endoscopy of College City Branch, Guangdong Provincial Hospital of Traditional Chinese Medicine, and Southern Hospital affiliated to Southern Medical University from June 2010 to January 2011. They were assigned to the @entity31 group (33 cases) and the @entity294 -predominant @entity1744 ( @entity1744 ) group (30 cases). Another 30 healthy subjects were recruited as a healthy control group. Peripheral blood mononuclear cells (PBMCs) in vitro intervened by different concentrations @entity7651 were taken from @entity31 @entity1 . @entity14283 gene expressions in vitro intervened by different concentrations @entity7651 were detected using Q-PCR. Expressions of @entity7116 ( @entity7116 ) , @entity8850 , phosphorylated- @entity7116 (p- @entity7116 ), and p- @entity8850 were detected using Western blot. Serum levels of @entity379 , @entity3646 , @entity650 , and @entity688 were measured by ELISA. Effects of different concentrations @entity7651 on expressions of PBMCs, and levels of @entity379 , @entity3646 , @entity688 of @entity31 @entity1 were also detected. RESULTS: Compared with the negative control group, 40   mol @entity7651 obviously decreased @entity14283 gene expression of @entity31 @entity1 (P <0. 01). Compared with the healthy control group and the @entity1744 group, p- @entity7116 / @entity7116 ratios increased, p- @entity8850 / @entity8850 ratios decreased, levels of @entity379 , @entity3646 , @entity688 all increased in the US group (all P <0. 05). Compared with the negative control, 5 and 10   mol @entity7651 groups, 20 and 40 moL @entity7651 obviously decreased p- @entity7116 / @entity7116 ratios (all P <0. 05); 20 and 40   moL @entity7651 obviously increased p- @entity8850 / @entity8850 ratios (all P <0. 05); 20 and 40   moL @entity7651 obviously lowered levels of @entity379 and @entity3646 , and elevated @entity688 levels (all P <0. 05). CONCLUSION: 40   moL @entity7651 could in vitro inhibit p- @entity7116 / @entity7116 ratios, adjust p- @entity8850 / @entity8850 ratios and related cytokines, thereby balancing the immunity and relieving inflammatory reactions of @entity31 .

title: [Effect of XXXX on signal transduction and activating transcription factor expression in @entity31 @entity1 ].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea']

entities_list: @entity7651 :: ('MESH:C038044', 'Chemical') :: ['baicalin']

entities_list: @entity31 :: ('MESH:D003093', 'Disease') :: ['ulcerative colitis', 'UC']

entities_list: @entity7116 :: ('6775', 'Gene') :: ['STAT4', 'signal transducer and activator of transcription 4']

entities_list: @entity21149 :: ('MESH:D004066', 'Disease') :: ['Digestive Disease']

entities_list: @entity1744 :: ('MESH:D043183', 'Disease') :: ['irritable bowel syndrome', 'IBS-D']

answer: @entity7651 :: (MESH:C038044,Chemical) :: ['baicalin']


abstract: OBJECTIVE: To explore the intervention of @entity7651 on signal transduction and activating transcription factor expression of @entity31 ( @entity31 ) @entity1 . METHODS: Recruited were @entity31 @entity1 at Outpatient Department of @entity21149 , Inpatient Department of @entity21149 , Center for Digestive Endoscopy of College City Branch, Guangdong Provincial Hospital of Traditional Chinese Medicine, and Southern Hospital affiliated to Southern Medical University from June 2010 to January 2011. They were assigned to the @entity31 group (33 cases) and the @entity294 -predominant @entity1744 ( @entity1744 ) group (30 cases). Another 30 healthy subjects were recruited as a healthy control group. Peripheral blood mononuclear cells (PBMCs) in vitro intervened by different concentrations @entity7651 were taken from @entity31 @entity1 . @entity14283 gene expressions in vitro intervened by different concentrations @entity7651 were detected using Q-PCR. Expressions of @entity7116 ( @entity7116 ) , @entity8850 , phosphorylated- @entity7116 (p- @entity7116 ), and p- @entity8850 were detected using Western blot. Serum levels of @entity379 , @entity3646 , @entity650 , and @entity688 were measured by ELISA. Effects of different concentrations @entity7651 on expressions of PBMCs, and levels of @entity379 , @entity3646 , @entity688 of @entity31 @entity1 were also detected. RESULTS: Compared with the negative control group, 40   mol @entity7651 obviously decreased @entity14283 gene expression of @entity31 @entity1 (P <0. 01). Compared with the healthy control group and the @entity1744 group, p- @entity7116 / @entity7116 ratios increased, p- @entity8850 / @entity8850 ratios decreased, levels of @entity379 , @entity3646 , @entity688 all increased in the US group (all P <0. 05). Compared with the negative control, 5 and 10   mol @entity7651 groups, 20 and 40 moL @entity7651 obviously decreased p- @entity7116 / @entity7116 ratios (all P <0. 05); 20 and 40   moL @entity7651 obviously increased p- @entity8850 / @entity8850 ratios (all P <0. 05); 20 and 40   moL @entity7651 obviously lowered levels of @entity379 and @entity3646 , and elevated @entity688 levels (all P <0. 05). CONCLUSION: 40   moL @entity7651 could in vitro inhibit p- @entity7116 / @entity7116 ratios, adjust p- @entity8850 / @entity8850 ratios and related cytokines, thereby balancing the immunity and relieving inflammatory reactions of @entity31 .

title: [Effect of @entity7651 on signal transduction and activating transcription factor expression in XXXX @entity1 ].

answer: @entity31 :: (MESH:D003093,Disease) :: ['ulcerative colitis']


abstract: OBJECTIVE: To explore the intervention of @entity7651 on signal transduction and activating transcription factor expression of @entity31 ( @entity31 ) @entity1 . METHODS: Recruited were @entity31 @entity1 at Outpatient Department of @entity21149 , Inpatient Department of @entity21149 , Center for Digestive Endoscopy of College City Branch, Guangdong Provincial Hospital of Traditional Chinese Medicine, and Southern Hospital affiliated to Southern Medical University from June 2010 to January 2011. They were assigned to the @entity31 group (33 cases) and the @entity294 -predominant @entity1744 ( @entity1744 ) group (30 cases). Another 30 healthy subjects were recruited as a healthy control group. Peripheral blood mononuclear cells (PBMCs) in vitro intervened by different concentrations @entity7651 were taken from @entity31 @entity1 . @entity14283 gene expressions in vitro intervened by different concentrations @entity7651 were detected using Q-PCR. Expressions of @entity7116 ( @entity7116 ) , @entity8850 , phosphorylated- @entity7116 (p- @entity7116 ), and p- @entity8850 were detected using Western blot. Serum levels of @entity379 , @entity3646 , @entity650 , and @entity688 were measured by ELISA. Effects of different concentrations @entity7651 on expressions of PBMCs, and levels of @entity379 , @entity3646 , @entity688 of @entity31 @entity1 were also detected. RESULTS: Compared with the negative control group, 40   mol @entity7651 obviously decreased @entity14283 gene expression of @entity31 @entity1 (P <0. 01). Compared with the healthy control group and the @entity1744 group, p- @entity7116 / @entity7116 ratios increased, p- @entity8850 / @entity8850 ratios decreased, levels of @entity379 , @entity3646 , @entity688 all increased in the US group (all P <0. 05). Compared with the negative control, 5 and 10   mol @entity7651 groups, 20 and 40 moL @entity7651 obviously decreased p- @entity7116 / @entity7116 ratios (all P <0. 05); 20 and 40   moL @entity7651 obviously increased p- @entity8850 / @entity8850 ratios (all P <0. 05); 20 and 40   moL @entity7651 obviously lowered levels of @entity379 and @entity3646 , and elevated @entity688 levels (all P <0. 05). CONCLUSION: 40   moL @entity7651 could in vitro inhibit p- @entity7116 / @entity7116 ratios, adjust p- @entity8850 / @entity8850 ratios and related cytokines, thereby balancing the immunity and relieving inflammatory reactions of @entity31 .

title: [Effect of @entity7651 on signal transduction and activating transcription factor expression in @entity31 XXXX ].

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: We report two cases of @entity2167 . Case 1: A 44-year-old @entity1 suffered from severe itching in the right external auditory meatus for a year, and had also had @entity4013 unguium for several years. He visited our outpatient clinic because of scaly erythema which had developed on the auricle. Otoscopic examination revealed yellow-brown dry cerumen and redness from the cartilaginous to the bony portion of the external auditory meatus. Case 2: A 14-year-old @entity1 , the son of Case 1, suffered from severe itching in the left external auditory meatus. He scratched the auditory meatus with an earpick which his father had used. Otoscopic examination revealed a similar lesion as in the father's case, although he had no history of @entity4013 elsewhere on his body, including the auricle. Direct examination using a KOH method of the cerumen from both cases demonstrated numerous fungal elements. Fungal culture identified @entity12734 . Both cases were successfully treated with oral @entity2059 . We suggest that infection from father to son was transferred by the earpick.

title: [Two cases of XXXX ].

entities_list: @entity4013 :: ('MESH:D014005', 'Disease') :: ['dermatophytosis', 'tinea']

entities_list: @entity2167 :: ('MESH:D006311', 'Disease') :: ['dermatophytosis of the external auditory meatus']

entities_list: @entity2059 :: ('MESH:D017964', 'Chemical') :: ['itraconazole']

entities_list: @entity12734 :: ('5551', 'Species') :: ['Trichophyton rubrum']

answer: @entity2167 :: (MESH:D006311,Disease) :: ['dermatophytosis of the external auditory meatus']


abstract: UNASSIGNED: Toll  -like receptors have been utilized in cancer therapeutic strategies in recent years. To the best of our knowledge, the systemic use of the @entity22532 ( @entity22532 ) agonist has not been investigated in a @entity0 model. In the current study, @entity5 growth following drug therapy was examined. Immunofluorescence and TUNEL staining were performed in order to examine the @entity5 vasculature and apoptosis, respectively. In addition, immunohistochemistry was used to assess @entity518 in @entity5 tissues. Activated CD4+  T cells in the peripheral blood were examined by flow cytometry. In the present study, it was identified that the @entity22532 agonist, R848, exhibited a robust antitumoral effect. R848 @entity5 and induced @entity5 cell apoptosis. In addition, R848 increased high mobility group box  1 expression in @entity5 tissues and activated CD4+ T cells in the peripheral blood. A synergistic antitumoral effect of R848 and the anti  -angiogenic agent, @entity2240 , was observed. The present findings suggest that the @entity22532 agonist may be a potential adjuvant to potentiate the effect of anti  -angiogenic therapy.

title: Toll  -like receptor  7/8 agonist, R848, exhibits antitumoral effects in a XXXX model.

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity2240 :: ('MESH:C473478', 'Chemical') :: ['sunitinib']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'reduced tumor vasculature']

answer: @entity0 :: (MESH:D001943,Disease) :: ['breast cancer']


abstract: BACKGROUND: @entity5426 ( @entity5426 ) are rare @entity5 of vascular origin with a variable behavior and overall poor prognosis. We sought to assess the outcomes of @entity1 treated for metastatic disease. METHODS: We performed a retrospective analysis of 119 @entity1 treated for metastatic @entity5426 . Outcomes and efficacy measurements of the first and subsequent lines of treatment were analyzed. RESULTS: Median age was 61 years, and the most frequent primary sites were chest wall/breast (31%), viscera (22%) and head/neck (20%). Seventy-three (61%) and 46 (39%) @entity1 received >= 2 and >= 3 lines of therapy, respectively. The most commonly used agents included @entity6023 and @entity8253 . Median overall survival was 12.1 months. Median times to @entity5 progression were 3.5 months for first line, 3.7 months for second line and 2.7 months for third line. Among 48 @entity1 evaluable per RECIST, the overall response rate to first line was 30% and <10% in subsequent lines. @entity632 , liposomal @entity632 and @entity6023 resulted in similar response rates and survival, and there was no apparent benefit for combination chemotherapy. CONCLUSION: Despite reasonable response rates in the first-line setting, benefit from systemic therapy is short-lived in metastatic @entity5426 , and outcomes are poor. @entity632 , liposomal @entity632 and @entity6023 are reasonable and appropriate choices for monotherapy.    2015 S. Karger AG, Basel.

title: Outcomes of Systemic Therapy for @entity1 with XXXX .

entities_list: @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin', 'Doxorubicin']

entities_list: @entity8253 :: ('MESH:D018943', 'Chemical') :: ['anthracyclines']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

entities_list: @entity5426 :: ('MESH:D006394', 'Disease') :: ['AS', 'Angiosarcomas']

answer: @entity5426 :: (MESH:D006394,Disease) :: ['Metastatic Angiosarcoma']


abstract: BACKGROUND: @entity5426 ( @entity5426 ) are rare @entity5 of vascular origin with a variable behavior and overall poor prognosis. We sought to assess the outcomes of @entity1 treated for metastatic disease. METHODS: We performed a retrospective analysis of 119 @entity1 treated for metastatic @entity5426 . Outcomes and efficacy measurements of the first and subsequent lines of treatment were analyzed. RESULTS: Median age was 61 years, and the most frequent primary sites were chest wall/breast (31%), viscera (22%) and head/neck (20%). Seventy-three (61%) and 46 (39%) @entity1 received >= 2 and >= 3 lines of therapy, respectively. The most commonly used agents included @entity6023 and @entity8253 . Median overall survival was 12.1 months. Median times to @entity5 progression were 3.5 months for first line, 3.7 months for second line and 2.7 months for third line. Among 48 @entity1 evaluable per RECIST, the overall response rate to first line was 30% and <10% in subsequent lines. @entity632 , liposomal @entity632 and @entity6023 resulted in similar response rates and survival, and there was no apparent benefit for combination chemotherapy. CONCLUSION: Despite reasonable response rates in the first-line setting, benefit from systemic therapy is short-lived in metastatic @entity5426 , and outcomes are poor. @entity632 , liposomal @entity632 and @entity6023 are reasonable and appropriate choices for monotherapy.    2015 S. Karger AG, Basel.

title: Outcomes of Systemic Therapy for XXXX with @entity5426 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

answer: @entity1 :: (9606,Species) :: ['Patients']


abstract: An asymptomatic 26-year-old @entity1 with mild @entity17443 (11.6 g Hb/dl) was studied. All biochemical parameters, bone marrow histology and cytogenetics were normal. The Ham's and sucrose tests were negative. A flow cytometric analysis revealed that @entity9819 and @entity1009 staining was absent in 20% and 21% of the granulocytes, but erythrocytes and @entity2280 -positive bone marrow cells were @entity9819 and @entity1009 positive. Seven months after the initial study, the @entity1 suffered an episode of @entity8763 , with mild @entity417 , moderate @entity882 and a weak positive sucrose lysis test. A new flow cytometric analysis disclosed an increased percentage of @entity9819 and @entity1009 negative granulocytes and a 25% of erythrocytes with an intermediate pattern of fluorescence after @entity1009 labelling. At fourteen months, a population of @entity9819 -deficient erythrocytes was detected and the Ham's test became positive. The present report is, to our knowledge, the first case of smoldering @entity7965 in a @entity1 with no previous @entity2150 , or evident @entity3043 . The diagnosis was established by flow cytometry of peripheral blood granulocytes, with apparently phenotipically normal progenitor cells in an early stage of the disease. Flow cytometry appears to be a useful tool in our knowledge of @entity7965 evolution.

title: De novo smoldering XXXX : a flow cytometric diagnosis.

entities_list: @entity1 :: ('9606', 'Species') :: ['woman', 'patient']

entities_list: @entity17443 :: ('MESH:D000748', 'Disease') :: ['macrocytic anemia']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia']

entities_list: @entity8763 :: ('MESH:D006456', 'Disease') :: ['hemoglobinuria']

entities_list: @entity2150 :: ('MESH:D000741', 'Disease') :: ['aplastic anemia']

entities_list: @entity7965 :: ('MESH:D006457', 'Disease') :: ['paroxysmal nocturnal hemoglobinuria']

entities_list: @entity3043 :: ('MESH:D010198', 'Disease') :: ['pancytopenia']

answer: @entity7965 :: (MESH:D006457,Disease) :: ['paroxysmal nocturnal hemoglobinuria']


abstract: INTRODUCTION AND OBJECTIVES: The natural history of @entity13088 remains unclear, mainly due to concurrent @entity301 or @entity101 . Since the presence of confounding factors is less likely in youngsters, they constitute a suitable study model to analyze early stages of @entity13088 . @entity1 AND METHODS: We screened 33 young normotensive asymptomatic @entity1 with @entity6 . Mean age was 28 +/- 8 y (range 18 to 46 y) and there were 14 @entity1 . RESULTS: 2-D Echo showed normal left ventricular size and wall motion in all @entity1 but one. Radionuclide basal ejection fraction was 56.5 +/- 6.6% and increased to 63 +/- 7.4% (p < 0.02) on exercise. According to Rozansky criteria, 16 @entity1 had an abnormal response. Abnormal stress sestamibi was detected in 18 @entity1 and only 3 had reversible defects. Coronary angiography was performed in 11 @entity1 with at least one abnormal non-invasive study response. Coronary angiography revealed normal vessels in all @entity1 and left anterior descending blood flow velocity (Doppler) increased 4 fold after @entity3302 infusion. Left ventricular biopsies showed @entity1184 (either nuclear or cellular) in 11, myocytolysis in 6, @entity82 in 9 and lipid deposits in 4. Morphometric analysis of cardiac samples comparing the @entity6 group and a control group showed that the volume fraction of @entity82 (0.19 +/- 0.06 vs 0.10 +/- 0.06; p < 0.01), fiber area -mu2- (1,062 +/- 547 vs 600 +/- 167; p < 0.02) and fiber diameter -mu- (24.2 +/- 3.3 vs 15.1 +/- 3.4; p < 0.001) were higher in the former; and volume fraction of the myocytes was higher in the latter (0.71 +/- 0.006 vs 0.89 +/- 0.07; p < 0.001). CONCLUSIONS: @entity1002 , not related to @entity453 , is frequent in asymptomatic young @entity6 @entity1 . Abnormal pathologic findings are common in the type of cell @entity1184 , @entity82 , myocytolysis and lipid deposits.

title: [Anatomopathological bases of latent ventricular dysfunction in insulin-dependent XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS', 'men']

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['interstitial fibrosis', 'fibrosis']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['type I diabetes mellitus', 'diabetic']

entities_list: @entity301 :: ('MESH:D003327', 'Disease') :: ['coronary disease']

entities_list: @entity13088 :: ('MESH:D058065', 'Disease') :: ['diabetic cardiomyopathy']

entities_list: @entity1184 :: ('MESH:D006984', 'Disease') :: ['hypertrophy']

entities_list: @entity3302 :: ('MESH:D010208', 'Chemical') :: ['papaverine']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary atherosclerosis or small vessel disease']

entities_list: @entity1002 :: ('MESH:D018487', 'Disease') :: ['Left ventricular dysfunction']

answer: @entity6 :: (MESH:D003920,Disease) :: ['diabetics']


abstract: OBJECTIVE: Increased peritoneal vasculature has been reported in long-term @entity298 ( @entity298 ), and vascular endothelial growth factors (VEGFs) have been found in dialysate. High concentrations of @entity413 or @entity880 , @entity413 degradation products (GDPs), and low pH of dialysis solutions are all possible factors in increased peritoneal @entity7 synthesis. In this study, we investigated the effects of high @entity413 dialysis solutions on @entity7 synthesis by peritoneal vascular endothelial cells (PVECs). METHODS: The PVECs were isolated from @entity35 omentum and were incubated for 4 hours in three different culture media [M199 media (control), conventional dialysis solutions containing 4.25% @entity413 diluted with an equal volume of M199 media (HGD), and M199 media containing 118 mmol/L @entity2656 as an osmolar control ( @entity2656 )]. Levels of @entity7 protein in the culture supernatant were measured by ELISA, and mRNA expression was determined by Northern blot analysis. Data are presented as percent of control. RESULTS: After incubation for 4 hours, the number of cells did not differ between the 3 groups. Levels of @entity7 in culture supernatant were significantly higher in the HGD group (124% +/- 19%, p = 0.006) as compared with the control and @entity2656 (85% +/- 10%) groups. The mRNA expression of @entity7 appeared to be higher in the HGD group (128% +/- 49%) than in the control and @entity2656 (94% +/- 18%) groups. CONCLUSION: High @entity413 dialysis solutions increased @entity7 synthesis by PVECs. The relationship between @entity7 synthesis by PVECs and neovascularization of the peritoneum observed in long-term @entity298 @entity1 has to be studied further.

title: High XXXX dialysis solutions increase synthesis of vascular endothelial growth factors by peritoneal vascular endothelial cells.

entities_list: @entity2656 :: ('MESH:D008353', 'Chemical') :: ['mannitol']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity298 :: ('MESH:D010538', 'Disease') :: ['peritoneal dialysis', 'PD']

entities_list: @entity880 :: ('MESH:D019344', 'Chemical') :: ['lactate']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

answer: @entity413 :: (MESH:D005947,Chemical) :: ['glucose']


abstract: UNASSIGNED: @entity3079 (AuNPs) of ~5nm core size and Zeta-potential of -35mV, having absorption maximum and plasmon resonance in the range of 510-570nm, were studied as a potential @entity3529 -channel opener in vascular smooth muscle (SM) cells. Experimental design of the study comprised SM contractile recordings. When externally applied to the organ bath, AuNPs (10(-6)-3*10(-4)M) led to decrease in amplitude of @entity1063 -induced contractions in a concentration-dependent and endothelium-independent manner in SM thoracic aorta, with mean value of pD2 (-log EC50) 4.2  0.03, Emax=55  4%. Being added to the bath solution in concentration of 10(-4)M, AuNPs significantly increased whole cell peak outward current at +70mV from 32  2pA/pF to 59  5pA/pF (n=14, P<0.05). External irradiation using a 5mW/532nm green laser, to facilitate plasmon resonance, led to an increment in the AuNPs-induced macroscopic outward @entity972 current (IK) from 59  5pA/pF to 74  1pA/pF (n=10, P<0.05). @entity39271 (500nM), when added to the external bathing solution, significantly decreased AuNPs-induced increment of IK in SM cells. Single channel recordings provided a direct confirmation of @entity9476 activation by AuNPs at the single-channel level. Application of AuNPs to the bath potentiated @entity9476 activity with a delay of 1-2min, as was seen initially by more frequent channel openings followed by the progressive appearance of additional open levels corresponding to multiple openings of channels with identical single-channel amplitudes. Eventually, after 10-15min in the presence of AuNPs and especially when combined with the green laser illumination, there was a massive increase in channel activity with >10 channels evident. When irradiated by laser, AuNPs significantly increased the amplitude of maximal AuNPs-induced relaxation from 55  5% to 85  5% (n=10, P<0.05) while the sensitivity of SM to AuNPs was without changes. In summary, plasmonic AuNPs possess the ability to activate @entity9476 channel opening in vascular SM. Laser irradiation facilitates this effect due to local plasmon resonance that, in turn, further increases @entity9476 channel activity causing SM relaxation.

title: Plasmonic gold nanoparticles possess the ability to open XXXX channels in rat thoracic aorta smooth muscles in a remote control manner.

entities_list: @entity3079 :: ('MESH:D002288', 'Disease') :: ['Colloidal gold nanoparticles']

entities_list: @entity39271 :: ('MESH:C048220', 'Chemical') :: ['Paxilline']

entities_list: @entity972 :: ('MESH:D011188', 'Chemical') :: ['potassium']

entities_list: @entity1063 :: ('MESH:D009638', 'Chemical') :: ['norepinephrine']

answer: @entity972 :: (MESH:D011188,Chemical) :: ['potassium']


abstract: RATIONALE: It has been proposed that @entity1234 ( @entity1865 ) reflects free @entity26 -radical lipid peroxidation and can be useful as a biomarker to track this process. For the analysis of @entity1865 molecules in humid air by selected ion flow tube mass spectrometry (SIFT- @entity15 ), the rate coefficients and the ion product distributions for the reactions of the SIFT- @entity15 reagent ions with volatile @entity1865 in the presence of water vapour are required. METHODS: The SIFT technique has been used to determine the rate coefficients and ion product distributions for the reactions of @entity32909 , NO(+) and @entity3612 (+   ) with gas-phase @entity1865 . In support of the SIFT- @entity15 analysis of @entity1865 , solid-phase microextraction, SPME, coupled with gas chromatography/mass spectrometry, GC/ @entity15 , has been used to confirm the identification of @entity1865 . RESULTS: The primary product ions have been identified for the reactions of @entity32909 , NO(+) and @entity3612 (+   ) with @entity1865 and the formation of their hydrates formed in humid samples is described. The following combinations of reagent and the analyte ions (given as m/z values) have been adopted for SIFT- @entity15 analyses of @entity1865 in the gas phase: @entity32909 : 109; NO(+): 89, 102; @entity3612 : 72, 90, 108, 126. The detection and quantification of @entity1865 released by a cell culture by SIFT- @entity15 are demonstrated. CONCLUSIONS: This detailed study has provided the kinetics data required for the SIFT- @entity15 analysis of @entity1865 in humid air, including exhaled breath and the headspace of liquid-phase biogenic media. The detection and quantification by SIFT- @entity15 of @entity1865 released by a cell culture are demonstrated. Copyright    2015 John Wiley _ Sons, Ltd.

title: Direct detection and quantification of XXXX vapour in humid air using selected ion flow tube mass spectrometry supported by gas chromatography/mass spectrometry.

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity1234 :: ('MESH:D008315', 'Chemical') :: ['malondialdehyde']

answer: @entity1234 :: (MESH:D008315,Chemical) :: ['malondialdehyde']


abstract: BACKGROUND: In 2006, Australia adopted a revised cervical cytology terminology system, known as the Australian Modified Bethesda System (AMBS). One substantial change in the AMBS was the introduction of the diagnostic category of @entity1358 ( @entity1358 ) of undetermined significance. AIM: The aim of this study was to investigate the incidence of histologically confirmed high-grade cervical @entity1141 ( @entity5 ( @entity5 ) grades 2 and 3 and @entity15709 (ACIS)), @entity2622 and @entity1204 in @entity1 presenting with @entity1358 on cervical cytology. METHODS: A seven-year retrospective study examining clinical outcomes of @entity1 with @entity1358 on a screening cervical smear. Cytology and histology results were extracted from the Western Australia Cervical Screening Registry, and time-to-event analysis was used to predict the odds of having or developing in  situ and invasive @entity5 . RESULTS: @entity1358 was reported in index smears from 0.093% (584/622754) @entity1 during the study period. No follow-up was available in 35 @entity1358 cases. Sixty-five of the remaining 549 @entity1 (11.8%) had, or developed, high-grade cervical @entity1141 within five years of their index @entity1358 diagnosis. @entity1204 was diagnosed in 21 @entity1 and @entity5 in four @entity1 during the follow-up period. CONCLUSION: Cytologic demonstration of @entity1358 requires careful gynaecologic evaluation, particularly in younger @entity1 who may be found to have either high-grade squamous ( @entity5 ) or glandular (ACIS) lesions, while in older @entity1 , the possibility of @entity1478 needs to be considered.

title: Risk of high-grade cervical @entity1141 and gynaecological @entity5 following the cytologic diagnosis of XXXX of undetermined significance: A retrospective study of a state-wide screening population in Western Australia.

entities_list: @entity1204 :: ('MESH:D016889', 'Disease') :: ['endometrial carcinoma', 'Endometrial cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cervical intra-epithelial neoplasia', 'CIN', 'cervical cancer', 'neoplasia']

entities_list: @entity2622 :: ('MESH:D002583', 'Disease') :: ['cervical carcinoma']

entities_list: @entity1358 :: ('MESH:D002292', 'Disease') :: ['AEC', 'atypical endocervical cells']

entities_list: @entity1478 :: ('MESH:D014591', 'Disease') :: ['endometrial neoplasia']

entities_list: @entity15709 :: ('MESH:D065311', 'Disease') :: ['adenocarcinoma in  situ']

entities_list: @entity1141 :: ('MESH:C535662', 'Disease') :: ['dysplasia']

answer: @entity1358 :: (MESH:D002292,Disease) :: ['atypical endocervical cells']


abstract: BACKGROUND: In 2006, Australia adopted a revised cervical cytology terminology system, known as the Australian Modified Bethesda System (AMBS). One substantial change in the AMBS was the introduction of the diagnostic category of @entity1358 ( @entity1358 ) of undetermined significance. AIM: The aim of this study was to investigate the incidence of histologically confirmed high-grade cervical @entity1141 ( @entity5 ( @entity5 ) grades 2 and 3 and @entity15709 (ACIS)), @entity2622 and @entity1204 in @entity1 presenting with @entity1358 on cervical cytology. METHODS: A seven-year retrospective study examining clinical outcomes of @entity1 with @entity1358 on a screening cervical smear. Cytology and histology results were extracted from the Western Australia Cervical Screening Registry, and time-to-event analysis was used to predict the odds of having or developing in  situ and invasive @entity5 . RESULTS: @entity1358 was reported in index smears from 0.093% (584/622754) @entity1 during the study period. No follow-up was available in 35 @entity1358 cases. Sixty-five of the remaining 549 @entity1 (11.8%) had, or developed, high-grade cervical @entity1141 within five years of their index @entity1358 diagnosis. @entity1204 was diagnosed in 21 @entity1 and @entity5 in four @entity1 during the follow-up period. CONCLUSION: Cytologic demonstration of @entity1358 requires careful gynaecologic evaluation, particularly in younger @entity1 who may be found to have either high-grade squamous ( @entity5 ) or glandular (ACIS) lesions, while in older @entity1 , the possibility of @entity1478 needs to be considered.

title: Risk of high-grade cervical XXXX and gynaecological @entity5 following the cytologic diagnosis of @entity1358 of undetermined significance: A retrospective study of a state-wide screening population in Western Australia.

answer: @entity1141 :: (MESH:C535662,Disease) :: ['dysplasia']


abstract: BACKGROUND: In 2006, Australia adopted a revised cervical cytology terminology system, known as the Australian Modified Bethesda System (AMBS). One substantial change in the AMBS was the introduction of the diagnostic category of @entity1358 ( @entity1358 ) of undetermined significance. AIM: The aim of this study was to investigate the incidence of histologically confirmed high-grade cervical @entity1141 ( @entity5 ( @entity5 ) grades 2 and 3 and @entity15709 (ACIS)), @entity2622 and @entity1204 in @entity1 presenting with @entity1358 on cervical cytology. METHODS: A seven-year retrospective study examining clinical outcomes of @entity1 with @entity1358 on a screening cervical smear. Cytology and histology results were extracted from the Western Australia Cervical Screening Registry, and time-to-event analysis was used to predict the odds of having or developing in  situ and invasive @entity5 . RESULTS: @entity1358 was reported in index smears from 0.093% (584/622754) @entity1 during the study period. No follow-up was available in 35 @entity1358 cases. Sixty-five of the remaining 549 @entity1 (11.8%) had, or developed, high-grade cervical @entity1141 within five years of their index @entity1358 diagnosis. @entity1204 was diagnosed in 21 @entity1 and @entity5 in four @entity1 during the follow-up period. CONCLUSION: Cytologic demonstration of @entity1358 requires careful gynaecologic evaluation, particularly in younger @entity1 who may be found to have either high-grade squamous ( @entity5 ) or glandular (ACIS) lesions, while in older @entity1 , the possibility of @entity1478 needs to be considered.

title: Risk of high-grade cervical @entity1141 and gynaecological XXXX following the cytologic diagnosis of @entity1358 of undetermined significance: A retrospective study of a state-wide screening population in Western Australia.

answer: @entity5 :: (MESH:D009369,Disease) :: ['malignancies']


abstract: BACKGROUND/AIMS: Rituximab and glucocorticoids are a non-inferior alternative to @entity786 and glucocorticoid therapy for induction of remission in antineutrophil cytoplasmic antibody (ANCA) associated @entity1333 (AAV) @entity1 with moderate @entity8 . The efficacy and safety of this approach in @entity1 with severe @entity8 are unknown. We report the outcomes and safety profile of rituximab and glucocorticoid therapy for induction of remission in @entity1 with AAV and ANCA-negative @entity1333 presenting with severe @entity8 . METHODS: A multicenter, retrospective, cohort study was conducted between 2005 and 2014. @entity1 with new or relapsing disease with an estimated glomerular filtration rate (eGFR) of  <=20 ml/min/1.73 m(2) treated with rituximab and glucocorticoid induction with or without plasmapheresis were included. Fourteen @entity1 met the inclusion criteria. The primary outcomes were rate of remission and dialysis independence at 6 months. The secondary outcomes were eGFR at 6 months, @entity454 ( @entity454 ), survival rates and adverse events. RESULTS: All @entity1 were Caucasian, and 57% were male. The mean eGFR was 12 ml/min/1.73 m(2) at diagnosis. All @entity1 achieved remission with a median time to remission of 55 days. Seven @entity1 required dialysis at presentation of which 5 @entity1 recovered renal function and discontinued dialysis by 6-month follow-up. The mean eGFR for the 11 @entity1 without @entity454 who completed 6-month follow-up was 33 ml/min/1.73 m(2). Four @entity1 ultimately developed @entity454 , and one died during the follow-up period. CONCLUSION: @entity1 with AAV and severe @entity8 achieve high rates of remission and dialysis independence when treated with rituximab and glucocorticoids without @entity786 .    2015 S. Karger AG, Basel.

title: Treatment of Severe XXXX in ANCA Positive and Negative Small @entity1333 with Rituximab.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['renal impairment', 'renal disease']

entities_list: @entity1333 :: ('MESH:D014657', 'Disease') :: ['vasculitis']

entities_list: @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide']

entities_list: @entity454 :: ('MESH:D007676', 'Disease') :: ['end-stage renal disease', 'ESRD']

answer: @entity8 :: (MESH:D007674,Disease) :: ['Renal Disease']


abstract: BACKGROUND/AIMS: Rituximab and glucocorticoids are a non-inferior alternative to @entity786 and glucocorticoid therapy for induction of remission in antineutrophil cytoplasmic antibody (ANCA) associated @entity1333 (AAV) @entity1 with moderate @entity8 . The efficacy and safety of this approach in @entity1 with severe @entity8 are unknown. We report the outcomes and safety profile of rituximab and glucocorticoid therapy for induction of remission in @entity1 with AAV and ANCA-negative @entity1333 presenting with severe @entity8 . METHODS: A multicenter, retrospective, cohort study was conducted between 2005 and 2014. @entity1 with new or relapsing disease with an estimated glomerular filtration rate (eGFR) of  <=20 ml/min/1.73 m(2) treated with rituximab and glucocorticoid induction with or without plasmapheresis were included. Fourteen @entity1 met the inclusion criteria. The primary outcomes were rate of remission and dialysis independence at 6 months. The secondary outcomes were eGFR at 6 months, @entity454 ( @entity454 ), survival rates and adverse events. RESULTS: All @entity1 were Caucasian, and 57% were male. The mean eGFR was 12 ml/min/1.73 m(2) at diagnosis. All @entity1 achieved remission with a median time to remission of 55 days. Seven @entity1 required dialysis at presentation of which 5 @entity1 recovered renal function and discontinued dialysis by 6-month follow-up. The mean eGFR for the 11 @entity1 without @entity454 who completed 6-month follow-up was 33 ml/min/1.73 m(2). Four @entity1 ultimately developed @entity454 , and one died during the follow-up period. CONCLUSION: @entity1 with AAV and severe @entity8 achieve high rates of remission and dialysis independence when treated with rituximab and glucocorticoids without @entity786 .    2015 S. Karger AG, Basel.

title: Treatment of Severe @entity8 in ANCA Positive and Negative Small XXXX with Rituximab.

answer: @entity1333 :: (MESH:D014657,Disease) :: ['Vessel Vasculitis']


abstract: OBJECT: In recent years, fetal mesencephalic tissue transplant for the treatment of @entity191 ( @entity191 ) has been demonstrated to hold promise, but potential complications related to growth of allograft tissue have not been well described. This report explores the development and possible causation of a fatal cyst arising from a fetal transplant in the brain. METHODS: The authors report the case of a 52-year-old @entity1 who underwent bilateral putamenal fetal mesencephalic allograft transplant for @entity191 at another hospital. Twenty-three months later she presented to the authors' institution in a @entity772 . Admission computerized tomography and magnetic resonance (MR) studies revealed a contrast-enhancing mural nodule and associated large cyst arising from the left putamen and causing @entity2850 . Despite surgical decompression of the cyst, the @entity1 did not regain consciousness. Biopsy and autopsy specimens were obtained, along with an analysis of the cyst fluid. Genotyping of the nodule and the @entity1 's peripheral lymphocytes by using polymerase chain reaction-based microsatellite analysis was also performed. Biopsy samples and autopsy histopathological studies showed inflammatory cells, hemosiderin-laden macrophages, and @entity5219 . Scattered neurons and multiple rests of choroid plexus were also noted. The cyst had a thin wall and contained liquid that was identical in composition to cerebrospinal fluid (CSF). Genotyping demonstrated the presence of alleles in the nodule DNA that were not present in lymphocytic DNA, indicating that the nodule contained allograft tissue. CONCLUSIONS: The authors hypothesize that the choroid plexus tissue contained in the allograft resulted in CSF production and cyst formation at the transplant site, ultimately leading to the @entity1 's @entity3976 . The clinical history and large size of the mural nodule indicate slow growth of this allograft site and cyst over time. This case demonstrates that unusual patterns of tissue growth can occur in the brain after fetal tissue transplant and emphasizes the need for long-term monitoring of posttransplant @entity1 by means of MR imaging. Cell sorting should be considered to ensure transplant of pure neuronal and astroglial populations.

title: Fatal cyst formation after fetal mesencephalic allograft transplant for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['woman', 'patients', 'patient']

entities_list: @entity3976 :: ('MESH:D004677', 'Disease') :: ['herniation syndrome']

entities_list: @entity5219 :: ('MESH:D005911', 'Disease') :: ['astrocytosis']

entities_list: @entity2850 :: ('MESH:D009408', 'Disease') :: ['brainstem compression']

entities_list: @entity191 :: ('MESH:D010300', 'Disease') :: ["Parkinson's disease", 'PD']

answer: @entity191 :: (MESH:D010300,Disease) :: ['Parkinson's disease']


abstract: The authors report the occurrence of ipsilateral transient @entity15265 during balloon test occlusion (BTO) of the cervical internal carotid artery (ICA) and discuss the involved pathomechanisms. The authors reviewed their series of 129 BTOs of the ICA performed between 1989 and 1996. Two @entity1 developed @entity809 and transient palsies of the third through sixth cranial nerves during test occlusion of the cervical ICA. The tests were performed prior to planned permanent @entity432 for the treatment of a @entity135 in one @entity1 and a giant cavernous carotid artery @entity439 in the other. The @entity1 ' symptoms resolved with @entity661 . When the balloon was subsequently inflated above the inferior cavernous sinus artery (ICSA), one of the @entity1 complained of mild facial discomfort. There was no @entity425 or mental status change during test occlusion in either @entity1 . Angiography demonstrated good filling of the ipsilateral intracranial circulation via collateral vessels of the circle of Willis. In these two cases, the cranial nerves in the cavernous sinus were likely supplied by the ICA via the meningohypophyseal trunk and the ICSA. In each case, there was excellent blood supply to the ipsilateral cerebral hemisphere; however, there was probably inadequate retrograde filling of the cranial nerve collateral vessels located where the meningohypophyseal trunk and ICSA originated. These cases emphasize the importance of a patent external carotid artery-ICA connection for successful cervical @entity432 . Neurological examination during BTO was critical to interpret the clinical manifestations caused by the hemodynamic changes.

title: XXXX during balloon test occlusion of the cervical internal carotid artery. Report of two cases.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity135 :: ('MESH:D006258', 'Disease') :: ['neck sarcoma']

entities_list: @entity809 :: ('MESH:D010292', 'Disease') :: ['facial paresthesias']

entities_list: @entity425 :: ('MESH:D018908', 'Disease') :: ['contralateral weakness']

entities_list: @entity15265 :: ('MESH:D020226', 'Disease') :: ['cavernous sinus syndrome']

entities_list: @entity439 :: ('MESH:D000783', 'Disease') :: ['aneurysm']

entities_list: @entity661 :: ('MESH:D054549', 'Disease') :: ['deflation of the balloon']

entities_list: @entity432 :: ('MESH:D001157', 'Disease') :: ['carotid artery occlusion']

answer: @entity15265 :: (MESH:D020226,Disease) :: ['Cavernous sinus syndrome']


abstract: BACKGROUND: Exposure to @entity14911 ( @entity14912 ) may potentially disturb fetal Leydig cell hormone production and male genital development. OBJECTIVES: We aimed to study the associations between levels of amniotic fluid @entity14912 , fetal @entity479 hormone, and @entity32407 ( @entity32407 ) and the prevalence of @entity246 and @entity2650 . METHODS: Using the Danish National @entity1 Registry, we selected 270 @entity246 cases, 75 @entity2650 cases, and 300 controls with stored maternal amniotic fluid samples available in a Danish pregnancy-screening biobank (1980-1996). We used mass spectrometry to measure @entity14912 in amniotic fluid from 645 @entity1 and @entity479 hormones in samples from 545 @entity1 . @entity32407 was measured by immunoassay from 475 @entity1 . Associations between @entity14912 concentration in amniotic fluid, hormone levels, and genital @entity600 were assessed by confounder-adjusted linear and logistic regression. RESULTS: The highest tertile of @entity14912 exposure (> 1.4 ng/mL) in amniotic fluid was associated with a 40% (95% CI: -69, -11%) lower @entity32407 level and an 18% (95% CI: 7, 29%) higher @entity251 level compared with the lowest tertile (< 0.8 ng/mL). Amniotic fluid @entity14912 concentration was not associated with @entity246 or @entity2650 . CONCLUSIONS: Environmental @entity14912 exposure was associated with @entity479 hormone and @entity32407 concentrations in amniotic fluid, but was not associated with @entity246 or @entity2650 in our study population. Additional studies are needed to determine whether associations with fetal hormone levels may have long-term implications for reproductive health. Citation: Toft G, J  nsson BA, Bonde @entity6223 , N  rgaard-Pedersen B, @entity3918 , Cohen A, Lindh CH, Ivell R, Anand-Ivell R, Lindhard MS. 2016. @entity14911 concentrations in amniotic fluid, biomarkers of fetal Leydig cell function, and @entity246 and @entity2650 in Danish @entity1 (1980-1996). Environ Health Perspect 124:151-156;   http://dx.doi.org/10.1289/ehp.1409288.

title: @entity14911 Concentrations in Amniotic Fluid, Biomarkers of Fetal Leydig Cell Function, and XXXX and @entity2650 in Danish @entity1 (1980-1996).

entities_list: @entity1 :: ('9606', 'Species') :: ['Patient', 'boys', 'persons']

entities_list: @entity14911 :: ('MESH:C076994', 'Chemical') :: ['perfluorooctane sulfonate', 'Perfluorooctane sulfonate']

entities_list: @entity251 :: ('MESH:D013739', 'Chemical') :: ['testosterone']

entities_list: @entity2650 :: ('MESH:D007021', 'Disease') :: ['hypospadias']

entities_list: @entity246 :: ('MESH:D003456', 'Disease') :: ['cryptorchidism']

entities_list: @entity600 :: ('MESH:D000014', 'Disease') :: ['malformations']

entities_list: @entity32407 :: ('3640', 'Gene') :: ['INSL3', 'insulin-like factor 3']

entities_list: @entity3918 :: ('MESH:D009223', 'Disease') :: ['Hougaard DM']

answer: @entity246 :: (MESH:D003456,Disease) :: ['Cryptorchidism']


abstract: BACKGROUND: Exposure to @entity14911 ( @entity14912 ) may potentially disturb fetal Leydig cell hormone production and male genital development. OBJECTIVES: We aimed to study the associations between levels of amniotic fluid @entity14912 , fetal @entity479 hormone, and @entity32407 ( @entity32407 ) and the prevalence of @entity246 and @entity2650 . METHODS: Using the Danish National @entity1 Registry, we selected 270 @entity246 cases, 75 @entity2650 cases, and 300 controls with stored maternal amniotic fluid samples available in a Danish pregnancy-screening biobank (1980-1996). We used mass spectrometry to measure @entity14912 in amniotic fluid from 645 @entity1 and @entity479 hormones in samples from 545 @entity1 . @entity32407 was measured by immunoassay from 475 @entity1 . Associations between @entity14912 concentration in amniotic fluid, hormone levels, and genital @entity600 were assessed by confounder-adjusted linear and logistic regression. RESULTS: The highest tertile of @entity14912 exposure (> 1.4 ng/mL) in amniotic fluid was associated with a 40% (95% CI: -69, -11%) lower @entity32407 level and an 18% (95% CI: 7, 29%) higher @entity251 level compared with the lowest tertile (< 0.8 ng/mL). Amniotic fluid @entity14912 concentration was not associated with @entity246 or @entity2650 . CONCLUSIONS: Environmental @entity14912 exposure was associated with @entity479 hormone and @entity32407 concentrations in amniotic fluid, but was not associated with @entity246 or @entity2650 in our study population. Additional studies are needed to determine whether associations with fetal hormone levels may have long-term implications for reproductive health. Citation: Toft G, J  nsson BA, Bonde @entity6223 , N  rgaard-Pedersen B, @entity3918 , Cohen A, Lindh CH, Ivell R, Anand-Ivell R, Lindhard MS. 2016. @entity14911 concentrations in amniotic fluid, biomarkers of fetal Leydig cell function, and @entity246 and @entity2650 in Danish @entity1 (1980-1996). Environ Health Perspect 124:151-156;   http://dx.doi.org/10.1289/ehp.1409288.

title: XXXX Concentrations in Amniotic Fluid, Biomarkers of Fetal Leydig Cell Function, and @entity246 and @entity2650 in Danish @entity1 (1980-1996).

answer: @entity14911 :: (MESH:C076994,Chemical) :: ['Perfluorooctane Sulfonate']


abstract: BACKGROUND: Exposure to @entity14911 ( @entity14912 ) may potentially disturb fetal Leydig cell hormone production and male genital development. OBJECTIVES: We aimed to study the associations between levels of amniotic fluid @entity14912 , fetal @entity479 hormone, and @entity32407 ( @entity32407 ) and the prevalence of @entity246 and @entity2650 . METHODS: Using the Danish National @entity1 Registry, we selected 270 @entity246 cases, 75 @entity2650 cases, and 300 controls with stored maternal amniotic fluid samples available in a Danish pregnancy-screening biobank (1980-1996). We used mass spectrometry to measure @entity14912 in amniotic fluid from 645 @entity1 and @entity479 hormones in samples from 545 @entity1 . @entity32407 was measured by immunoassay from 475 @entity1 . Associations between @entity14912 concentration in amniotic fluid, hormone levels, and genital @entity600 were assessed by confounder-adjusted linear and logistic regression. RESULTS: The highest tertile of @entity14912 exposure (> 1.4 ng/mL) in amniotic fluid was associated with a 40% (95% CI: -69, -11%) lower @entity32407 level and an 18% (95% CI: 7, 29%) higher @entity251 level compared with the lowest tertile (< 0.8 ng/mL). Amniotic fluid @entity14912 concentration was not associated with @entity246 or @entity2650 . CONCLUSIONS: Environmental @entity14912 exposure was associated with @entity479 hormone and @entity32407 concentrations in amniotic fluid, but was not associated with @entity246 or @entity2650 in our study population. Additional studies are needed to determine whether associations with fetal hormone levels may have long-term implications for reproductive health. Citation: Toft G, J  nsson BA, Bonde @entity6223 , N  rgaard-Pedersen B, @entity3918 , Cohen A, Lindh CH, Ivell R, Anand-Ivell R, Lindhard MS. 2016. @entity14911 concentrations in amniotic fluid, biomarkers of fetal Leydig cell function, and @entity246 and @entity2650 in Danish @entity1 (1980-1996). Environ Health Perspect 124:151-156;   http://dx.doi.org/10.1289/ehp.1409288.

title: @entity14911 Concentrations in Amniotic Fluid, Biomarkers of Fetal Leydig Cell Function, and @entity246 and XXXX in Danish @entity1 (1980-1996).

answer: @entity2650 :: (MESH:D007021,Disease) :: ['Hypospadias']


abstract: BACKGROUND: Exposure to @entity14911 ( @entity14912 ) may potentially disturb fetal Leydig cell hormone production and male genital development. OBJECTIVES: We aimed to study the associations between levels of amniotic fluid @entity14912 , fetal @entity479 hormone, and @entity32407 ( @entity32407 ) and the prevalence of @entity246 and @entity2650 . METHODS: Using the Danish National @entity1 Registry, we selected 270 @entity246 cases, 75 @entity2650 cases, and 300 controls with stored maternal amniotic fluid samples available in a Danish pregnancy-screening biobank (1980-1996). We used mass spectrometry to measure @entity14912 in amniotic fluid from 645 @entity1 and @entity479 hormones in samples from 545 @entity1 . @entity32407 was measured by immunoassay from 475 @entity1 . Associations between @entity14912 concentration in amniotic fluid, hormone levels, and genital @entity600 were assessed by confounder-adjusted linear and logistic regression. RESULTS: The highest tertile of @entity14912 exposure (> 1.4 ng/mL) in amniotic fluid was associated with a 40% (95% CI: -69, -11%) lower @entity32407 level and an 18% (95% CI: 7, 29%) higher @entity251 level compared with the lowest tertile (< 0.8 ng/mL). Amniotic fluid @entity14912 concentration was not associated with @entity246 or @entity2650 . CONCLUSIONS: Environmental @entity14912 exposure was associated with @entity479 hormone and @entity32407 concentrations in amniotic fluid, but was not associated with @entity246 or @entity2650 in our study population. Additional studies are needed to determine whether associations with fetal hormone levels may have long-term implications for reproductive health. Citation: Toft G, J  nsson BA, Bonde @entity6223 , N  rgaard-Pedersen B, @entity3918 , Cohen A, Lindh CH, Ivell R, Anand-Ivell R, Lindhard MS. 2016. @entity14911 concentrations in amniotic fluid, biomarkers of fetal Leydig cell function, and @entity246 and @entity2650 in Danish @entity1 (1980-1996). Environ Health Perspect 124:151-156;   http://dx.doi.org/10.1289/ehp.1409288.

title: @entity14911 Concentrations in Amniotic Fluid, Biomarkers of Fetal Leydig Cell Function, and @entity246 and @entity2650 in Danish XXXX (1980-1996).

answer: @entity1 :: (9606,Species) :: ['Boys']


abstract: BACKGROUND: Studies have come to conflicting conclusions about whether polymorphisms in the @entity15443 gene ( @entity15443 ) are associated with @entity5 risk. To help resolve this question, we meta-analyzed case-control studies in the literature. METHODS: PubMed, EMBASE, Cochrane Library, the Chinese Biological Medical Database and the Chinese National Knowledge Infrastructure Database were systematically searched to identify all case-control studies published through February 2015 examining any @entity15443 polymorphisms and risk of any type of @entity5 . Pooled odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were calculated. RESULTS: A total of 13 case-control studies involving 5,750 cases and 6,762 controls were analyzed. Analysis of the entire study population revealed a significant association between @entity70705 ( @entity13284 ) and overall @entity5 risk using a homozygous model (OR 0.82, 95%CI 0.72 to 0.94), heterozygous model (OR 0.84, 95%CI 0.76 to 0.93), dominant model (OR 0.85, 95%CI 0.75 to 0.97) and allele contrast model (OR 0.88, 95%CI 0.80 to 0.97). However, subgroup analysis showed that this association was significant only for Asians in the case of @entity14 . No significant associations were found between @entity70706 ( @entity6344 ) or @entity43645 ( @entity6993 ) and @entity5 risk, either in analyses of the entire study population or in analyses of subgroups. CONCLUSIONS: Our meta-analysis suggests that the @entity15443 @entity70705 ( @entity13284 ) polymorphism, but not @entity70706 ( @entity6344 ) or @entity43645 ( @entity6993 ), may be associated with @entity5 risk, especially risk of @entity14 in Asians. Large, well-designed studies are needed to verify our findings.

title: Three XXXX Polymorphisms and Cancer Risk: A Meta-Analysis of Case-Control Studies.

entities_list: @entity6344 :: ('c|SUB|C||T', 'DNAMutation') :: ['C/T']

entities_list: @entity15443 :: ('51094', 'Gene') :: ['adiponectin receptor 1', 'ADIPOR1']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity6993 :: ('c|SUB|C||G', 'DNAMutation') :: ['C/G']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer']

answer: @entity15443 :: (51094,Gene) :: ['ADIPOR1']


abstract: OBJECTIVE: Despite technical difficulties due to mediastinal @entity82 , repeat mediastinoscopy can be a valuable tool in the restaging of @entity2 . It provides essential pathological information on mediastinal invasion when selecting @entity1 for surgical resection after induction chemotherapy in stage IIIa disease. The aim of our study was to evaluate the feasibility, sensitivity and accuracy of repeat mediastinoscopy. METHODS: From 1994 to 1997 we performed a repeat mediastinoscopy in 15 @entity1 (13 @entity1 , two @entity1 ) with @entity153 . Their age ranged from 49 to 75 years. (mean 64.7). Seven @entity1 had induction chemotherapy for a @entity4153 with positive N2 nodes on mediastinoscopy. Four @entity1 had a second primary @entity2 , one had a locoregional recurrence of @entity153 . The other three had a first mediastinoscopy for other @entity2 , repeat mediastinoscopy being performed for staging of @entity5 . RESULTS: In all 15 @entity1 it was possible to perform a complete repeat mediastinoscopy. In one @entity1 repeat mediastinoscopy turned out to be false negative, so, in our series, sensitivity was 87.5%, specificity 100% and accuracy 93.7%. CONCLUSION: Previous mediastinoscopy is no contraindication for a repeat one. Repeat mediastinoscopy offers valuable pathological information in restaging of @entity2 .

title: Repeat mediastinoscopy in the staging of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient', 'men']

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrosis']

entities_list: @entity4153 :: ('MESH:D018288', 'Disease') :: ['non-small cell bronchogenic carcinoma']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['malignant disease']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer', 'contralateral lung cancer', 'reasons than lung cancer']

entities_list: @entity153 :: ('MESH:D002283', 'Disease') :: ['bronchogenic carcinoma']

answer: @entity2 :: (MESH:D008175,Disease) :: ['lung cancer']


abstract: PURPOSE: Several studies have documented that increased biopsy sampling, that is 6 versus 12 biopsy cores, can detect more @entity263 . It is unknown whether increased sampling of the prostate will detect a higher number of potentially insignificant @entity5 . MATERIALS AND METHODS: We searched the surgical pathology files at The Johns Hopkins Hospital for @entity1 in whom prostate needle biopsy was performed by a single urologist between April 1993 and April 2000, and subsequently underwent radical prostatectomy. @entity1 who underwent radical prostatectomy and had 8 core biopsies or less between March 1994 and August 1999 were also studied. Clinically significant @entity5 were defined as those with volume greater than 0.5 cc, Gleason score 7 or greater or nonorgan confined disease. RESULTS: A total of 297 @entity1 with a mean age of 60 years (range 36 to 75) were evaluated. Group 1 consisted of 107 @entity1 with 8 core biopsies or less, including 51 with 6, and group 2 comprised 190 @entity1 with 9 cores or greater, including 145 with 12. The 2 groups were equal in regard to @entity1486 , age, digital rectal examination and transrectal ultrasound gland volume at biopsy. The only difference between the groups was a higher number of cores with @entity5 in group 2 (mean 2.8 versus 2.1, p = 0.0006). Of the @entity1 who underwent radical prostatectomy 59.6% had Gleason score 6 or less, 26.3% 3+4, 6.7% 4+3 and 7.4% 8 to 9. There were 12.4% of @entity1 with positive margins, 36.4% extraprostatic extension, and 5.4% seminal vesicle invasion and/or lymph node @entity3 . @entity5 volumes averaged 1.1 cc (range 0.01 to 10.7) and 60.9% of @entity5 were greater than 0.5 cc. Clinically significant @entity5 were seen in 77.4% of @entity1 in group 1 and 74.6% in group 2. There was no significant difference in Gleason score, margin status, @entity5 volume, seminal vesicle invasion, or lymph node @entity3 between groups 1 and 2, or in a subset analysis of @entity1 with 6 versus 12 core biopsies. However, @entity1 in whom @entity5 was diagnosed with 9 core biopsies or greater were more likely to have organ confined disease (p = 0.02). CONCLUSIONS: Although increased sampling of the prostate does not increase the detection of potentially insignificant @entity5 , it does appear to detect earlier stage @entity5 .

title: Does increased needle biopsy sampling of the prostate detect a higher number of potentially insignificant XXXX ?

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'men']

entities_list: @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer', 'Tumor', 'tumors']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

entities_list: @entity1486 :: ('354', 'Gene') :: ['prostate specific antigen']

answer: @entity5 :: (MESH:D009369,Disease) :: ['tumors']


abstract: Surgical @entity1173 and/or drainage of @entity867 is considered to be the first-line treatment for @entity733 larger than 25 mm. This is ususally performed with the aid of CT-guided stereotaxy. A method of ultrasound guidance is presented that allows a single burr hole approach with real-time imaging of the whole procedure. A bayonet-like shaped ultrasound probe with tip dimension of 8 x 8 mm only (EUP-NS 32, Hitachi/Ecoscan) with frequencies of 3.5 and 5 MHz is used. After placement of a burr hole the target is identified by transdural insonation, a guideline is adjusted and a mounted puncture-adapter guides the cannula towards the lesion under real-time imaging control. Up to now 12 @entity733 in 10 @entity1 were treated. Visualization was always excellent. A second @entity1173 had to be performed twice. One abscess did not contain enough pus to be cured by @entity1173 and was removed by open surgery, another could not be tapped by the blunt cannula and was aspirated under stereotactic control using a sharp trocar. Outcome was excellent in 6 @entity1 and fair in 2 @entity1 but this was due to the pre-existing disease. Two @entity1 admitted in deep @entity772 died despite an emergency operation. The presented method has proven to be a very powerful guiding tool in the surgical treatment of @entity867 through a single burr hole approach.

title: Ultrasound-guided @entity1173 of XXXX through a single burr hole.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity733 :: ('MESH:D000038', 'Disease') :: ['abscesses']

entities_list: @entity867 :: ('MESH:D001922', 'Disease') :: ['brain abscesses']

entities_list: @entity1173 :: ('MESH:D053120', 'Disease') :: ['aspiration']

answer: @entity867 :: (MESH:D001922,Disease) :: ['brain abscesses']